This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Agilent officials believe that the comprehensive asset-management programs that it and a couple of key competitors have launched over the past couple of years are winning over a cost-conscious pharmaceutical industry, and will eventually be used by a growing number of large and mid-tier firms.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.